Skip to main content
Image of man holding a golf club in front of PLUVICTO "V" with a woman behind him and text reading,"About PLUVICTO" to his right

What is PLUVICTO and how does it work?

PLUVICTO is not chemotherapy.

It is the FIRST and ONLY radioligand therapy (RLT) for PSMA+ mCRPC.

  • RLT is a different type of radiation therapy that targets a biomarker called PSMA, which is present on many prostate cancer cells and also some healthy cells 

  • This means it is designed to find and attack PSMA+ cells, including cancer cells*

*May also damage healthy PSMA+ and other nearby cells.

 

Think of it in 3 steps

ATTACH: PLUVICTO attaches to PSMA proteins on the outside of a cell.

PLUVICTO mechanism of action 1

ABSORB: Then PLUVICTO is absorbed into the cell.

PLUVICTO mechanism of action 2

ATTACK: From inside the cell, PLUVICTO attacks. It releases radiation into its target, the PSMA+ cell, damaging or destroying with limited damage to surrounding cells.

PLUVICTO mechanism of action 3
mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.